MEP90508A - Nova farmaceutska smješa - Google Patents
Nova farmaceutska smješaInfo
- Publication number
- MEP90508A MEP90508A MEP-905/08A MEP90508A MEP90508A ME P90508 A MEP90508 A ME P90508A ME P90508 A MEP90508 A ME P90508A ME P90508 A MEP90508 A ME P90508A
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical composition
- new pharmaceutical
- relates
- present
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Ovaj pronalazak se odnosi na farmaceutske kombinacije, smješe i postupke za terapiju gojaznosti . Specifi čno se ovaj pronalazak odnosi na kombinaciju ili smješu koja sadrži inhibitor lipaza, prvenstveno orlistat i sekvenstrat žučnih kisjelina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00116393 | 2000-07-28 | ||
PCT/EP2001/008363 WO2002009815A2 (en) | 2000-07-28 | 2001-07-19 | New pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
ME00671B ME00671B (me) | 2011-12-20 |
MEP90508A true MEP90508A (hr) | 2011-12-20 |
Family
ID=8169384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-905/08A MEP90508A (hr) | 2000-07-28 | 2001-07-19 | Nova farmaceutska smješa |
Country Status (38)
Country | Link |
---|---|
US (5) | US6756364B2 (hr) |
EP (1) | EP1307264B1 (hr) |
JP (2) | JP4265911B2 (hr) |
KR (1) | KR100572785B1 (hr) |
CN (1) | CN100423715C (hr) |
AR (1) | AR033548A1 (hr) |
AT (1) | ATE279961T1 (hr) |
AU (2) | AU8969901A (hr) |
BR (1) | BR0112799B1 (hr) |
CA (1) | CA2416901C (hr) |
CZ (1) | CZ302087B6 (hr) |
DE (1) | DE60106623T2 (hr) |
EC (1) | ECSP034450A (hr) |
EG (1) | EG24357A (hr) |
ES (1) | ES2230362T3 (hr) |
GT (1) | GT200100152A (hr) |
HK (1) | HK1058636A1 (hr) |
HR (1) | HRP20030029B1 (hr) |
HU (1) | HU229292B1 (hr) |
IL (2) | IL154008A0 (hr) |
JO (1) | JO2320B1 (hr) |
MA (1) | MA26937A1 (hr) |
ME (1) | MEP90508A (hr) |
MX (1) | MXPA03000771A (hr) |
MY (1) | MY127247A (hr) |
NO (1) | NO330546B1 (hr) |
NZ (1) | NZ523684A (hr) |
PA (1) | PA8523201A1 (hr) |
PE (1) | PE20020336A1 (hr) |
PL (1) | PL204443B1 (hr) |
PT (1) | PT1307264E (hr) |
RS (1) | RS50397B (hr) |
RU (1) | RU2241462C2 (hr) |
SI (1) | SI1307264T1 (hr) |
TW (1) | TWI275395B (hr) |
UY (1) | UY26860A1 (hr) |
WO (1) | WO2002009815A2 (hr) |
ZA (1) | ZA200300456B (hr) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001289696B2 (en) * | 2000-07-28 | 2006-07-06 | Cheplapharm Arzneimittel Gmbh | New use of lipase inhibitors |
WO2002009815A2 (en) * | 2000-07-28 | 2002-02-07 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
US7033373B2 (en) | 2000-11-03 | 2006-04-25 | Satiety, Inc. | Method and device for use in minimally invasive placement of space-occupying intragastric devices |
US6558400B2 (en) | 2001-05-30 | 2003-05-06 | Satiety, Inc. | Obesity treatment tools and methods |
CN1325050C (zh) * | 2002-04-26 | 2007-07-11 | 霍夫曼-拉罗奇有限公司 | 包含脂肪酶抑制剂和葡甘露聚糖的药物组合物 |
US6746460B2 (en) | 2002-08-07 | 2004-06-08 | Satiety, Inc. | Intra-gastric fastening devices |
US7214233B2 (en) | 2002-08-30 | 2007-05-08 | Satiety, Inc. | Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach |
US7033384B2 (en) | 2002-08-30 | 2006-04-25 | Satiety, Inc. | Stented anchoring of gastric space-occupying devices |
AU2003263664B2 (en) * | 2002-09-09 | 2008-03-06 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Branched alpha-glucans for weight management |
US7220237B2 (en) | 2002-10-23 | 2007-05-22 | Satiety, Inc. | Method and device for use in endoscopic organ procedures |
DK2368554T3 (en) | 2003-04-08 | 2015-01-26 | Progenics Pharm Inc | A pharmaceutical composition comprising methylnaltrexone |
US7175638B2 (en) | 2003-04-16 | 2007-02-13 | Satiety, Inc. | Method and devices for modifying the function of a body organ |
US7097650B2 (en) | 2003-10-14 | 2006-08-29 | Satiety, Inc. | System for tissue approximation and fixation |
US7914543B2 (en) | 2003-10-14 | 2011-03-29 | Satiety, Inc. | Single fold device for tissue fixation |
US20050133416A1 (en) * | 2003-12-19 | 2005-06-23 | Bhan Opinder K. | Systems, methods, and catalysts for producing a crude product |
US20050177176A1 (en) | 2004-02-05 | 2005-08-11 | Craig Gerbi | Single-fold system for tissue approximation and fixation |
US8828025B2 (en) | 2004-02-13 | 2014-09-09 | Ethicon Endo-Surgery, Inc. | Methods and devices for reducing hollow organ volume |
CA2547934C (en) * | 2004-02-19 | 2013-05-21 | Abbott Laboratories | Methods of using gamma cyclodextrin to control blood glucose and insulin secretion |
AU2005218318A1 (en) | 2004-02-27 | 2005-09-15 | Ethicon Endo-Surgery, Inc | Methods and devices for reducing hollow organ volume |
US8628547B2 (en) | 2004-03-09 | 2014-01-14 | Ethicon Endo-Surgery, Inc. | Devices and methods for placement of partitions within a hollow body organ |
US8252009B2 (en) | 2004-03-09 | 2012-08-28 | Ethicon Endo-Surgery, Inc. | Devices and methods for placement of partitions within a hollow body organ |
US9028511B2 (en) | 2004-03-09 | 2015-05-12 | Ethicon Endo-Surgery, Inc. | Devices and methods for placement of partitions within a hollow body organ |
US8449560B2 (en) | 2004-03-09 | 2013-05-28 | Satiety, Inc. | Devices and methods for placement of partitions within a hollow body organ |
US7753870B2 (en) | 2004-03-26 | 2010-07-13 | Satiety, Inc. | Systems and methods for treating obesity |
US20050276781A1 (en) * | 2004-06-09 | 2005-12-15 | Ross Edward A | Molecularly imprinted phosphate binders for therapeutic use |
WO2006035296A1 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat |
US20060106288A1 (en) | 2004-11-17 | 2006-05-18 | Roth Alex T | Remote tissue retraction device |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
EP1861096B1 (en) * | 2005-03-07 | 2018-12-26 | The University of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
US20090208584A1 (en) * | 2005-06-09 | 2009-08-20 | Tomohiro Yoshinari | Solid preparation |
WO2006134591A2 (en) * | 2005-06-13 | 2006-12-21 | Yeda Research And Development Co. Ltd. | Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases |
AR056499A1 (es) * | 2005-09-06 | 2007-10-10 | Serapis Farmaceuticals Ltd | Compuestos |
CN101304739A (zh) * | 2005-11-08 | 2008-11-12 | 基酶有限公司 | 用于治疗高磷酸盐血症的含镁聚合物 |
NZ569756A (en) * | 2005-12-12 | 2011-07-29 | Allaccem Inc | Methods and systems for preparing antimicrobial films and coatings utilising polycyclic bridged ammonium salts |
EP1803714A1 (en) * | 2005-12-27 | 2007-07-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for preparing crystalline forms of orlistat |
JP2009524648A (ja) * | 2006-01-25 | 2009-07-02 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | アリルメルカプトカプトプリル(cpssa)及び関連非対称ジスルフィドを調製するための方法 |
US7749536B2 (en) * | 2006-02-14 | 2010-07-06 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture |
EP1818048B1 (en) * | 2006-02-14 | 2009-01-07 | Teva Pharmaceutical Industries, Inc. | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture |
KR20090051240A (ko) | 2006-09-01 | 2009-05-21 | 유에스브이 리미티드 | 세벨라머 염산염의 제조방법 및 그의 제형 |
US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
US7662373B2 (en) * | 2006-09-18 | 2010-02-16 | Thompson Ronald J | Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor |
US20080069906A1 (en) * | 2006-09-18 | 2008-03-20 | Thompson Ronald J | Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor |
GB0618725D0 (en) * | 2006-09-23 | 2006-11-01 | Jagotec Ag | Composition containing inhibitors of gastro-intestinal lipase |
WO2008070308A2 (en) * | 2006-10-24 | 2008-06-12 | Thompson Md Ronald J | Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o |
ZA200904573B (en) * | 2006-12-22 | 2010-09-29 | Ironwood Pharmaceuticals Inc | Compositions comprising bile acid sequestrants for treating esophageal disorders |
EP1944025A1 (en) * | 2007-01-09 | 2008-07-16 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions of orlistat |
ES2522908T3 (es) | 2007-02-21 | 2014-11-19 | Allaccem, Inc. | Composiciones a base de compuestos policíclicos con puente para la inhibición y el alivio de enfermedades |
SI2139890T1 (sl) | 2007-03-29 | 2014-12-31 | Wyeth Llc | Antagonisti perifernih opioidnih receptorjev in njih uporaba |
ES2765811T5 (es) | 2007-03-29 | 2024-02-27 | Progenics Pharm Inc | Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos |
CL2008000905A1 (es) | 2007-03-29 | 2008-08-22 | Progenics Pharm Inc | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. |
US20090023682A1 (en) * | 2007-07-19 | 2009-01-22 | Joseph Artiss | Composition Comprising Dietary Fat Complexer and Methods of Using Same |
US8188068B2 (en) * | 2007-08-10 | 2012-05-29 | Allaccem, Inc. | Bridged polycyclic compound based compositions for coating oral surfaces in pets |
US8153617B2 (en) * | 2007-08-10 | 2012-04-10 | Allaccem, Inc. | Bridged polycyclic compound based compositions for coating oral surfaces in humans |
US8153618B2 (en) * | 2007-08-10 | 2012-04-10 | Allaccem, Inc. | Bridged polycyclic compound based compositions for topical applications for pets |
US20090074833A1 (en) * | 2007-08-17 | 2009-03-19 | Whiteford Jeffery A | Bridged polycyclic compound based compositions for controlling bone resorption |
EP2219614A1 (en) * | 2007-10-15 | 2010-08-25 | Inventis DDS Pvt Limited | Pharmaceutical composition of orlistat |
CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
US20100016270A1 (en) * | 2008-06-20 | 2010-01-21 | Whiteford Jeffery A | Bridged polycyclic compound based compositions for controlling cholesterol levels |
US20100004218A1 (en) * | 2008-06-20 | 2010-01-07 | Whiteford Jeffery A | Bridged polycyclic compound based compositions for renal therapy |
KR20110059750A (ko) * | 2008-09-02 | 2011-06-03 | 유에스브이 리미티드 | 가교 폴리머 |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF OBESITY AND DIABETES |
GB0900350D0 (en) * | 2009-01-09 | 2009-02-11 | Cambridge Entpr Ltd | Formulations of viable bacteria for oral delivery |
EP2395987A1 (en) | 2009-02-12 | 2011-12-21 | Coöperatieve Mirzorg U.A., Arnhem | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
US20100330175A1 (en) * | 2009-06-24 | 2010-12-30 | Jobdevairakkam Christopher N | Cross-linked polyallylamine tablet core |
US20110152204A1 (en) * | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of Obesity or Diabetes with Bile Acid Sequestrants |
EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
RS60901B1 (sr) | 2010-11-08 | 2020-11-30 | Albireo Ab | Ibat inhibitori za lečenje oboljenja jetre |
WO2013049595A1 (en) * | 2011-09-29 | 2013-04-04 | Ethicon Endo-Surgery, Inc. | Methods and compositions of bile acids |
KR20190134828A (ko) | 2011-10-28 | 2019-12-04 | 루메나 파마수티컬즈, 인코포레이티드 | 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제 |
EP2591768B1 (en) * | 2011-11-14 | 2014-07-16 | Deva Holding Anonim Sirketi | Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents |
JP2013147488A (ja) * | 2011-12-21 | 2013-08-01 | Taisho Pharmaceutical Co Ltd | 固形製剤 |
GB201122213D0 (en) * | 2011-12-23 | 2012-02-01 | Norgine Bv | Compositions |
US8252312B1 (en) * | 2011-12-27 | 2012-08-28 | David Wong | Oral solid composition comprising a lipid absorption inhibitor |
US10695294B2 (en) | 2012-11-06 | 2020-06-30 | Sigrid Therapeutics Ab | Porous silica material for use as a pharmaceutical or dietary active ingredient |
TWI614017B (zh) | 2012-12-21 | 2018-02-11 | 財團法人國家衛生研究院 | 包含中孔洞矽奈米粒子之組成物的用途 |
RU2552926C1 (ru) * | 2014-06-23 | 2015-06-10 | Общество с ограниченной ответственностью "ПРОМОМЕД" | Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе |
KR102560954B1 (ko) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
US10743813B2 (en) | 2014-09-11 | 2020-08-18 | Rattan Nath | Diabetes control using postprandial feedback |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
JP6830969B2 (ja) * | 2016-02-09 | 2021-02-17 | アルビレオ・アクチボラグ | コレスチラミンペレット剤及びその調製のための方法 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
US11389545B2 (en) * | 2018-01-09 | 2022-07-19 | Aqua Regenerative Therapies Llc | Bioactive nanoparticles and methods for making same |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CN112312893A (zh) | 2018-06-20 | 2021-02-02 | 阿尔比里奥公司 | 奥德昔巴特的药物制剂 |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CN108685848B (zh) * | 2018-08-13 | 2020-09-01 | 中山万汉制药有限公司 | 一种奥利司他口服乳剂及其制备方法 |
NL2022615B1 (en) | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight |
CN111297826B (zh) * | 2020-04-20 | 2021-08-03 | 鲁南制药集团股份有限公司 | 一种稳定的奥利司他胶囊及其制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
IT1052819B (it) * | 1975-12-12 | 1981-07-20 | Fargal Pharmasint Lab Biochim | Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
DE3414609C1 (de) * | 1984-04-18 | 1985-06-20 | Daimler-Benz Ag, 7000 Stuttgart | Vorrichtung zur Beeinflussung eines Kuehlluftstromes |
IT1190349B (it) * | 1986-06-16 | 1988-02-16 | Prodotti Formenti Srl | Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle |
US5063210A (en) * | 1989-04-20 | 1991-11-05 | Lange Iii Louis G | Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption |
US5344453A (en) * | 1991-05-30 | 1994-09-06 | Boston Medical Products, Inc. | Thyroplasty implant |
US5616570A (en) * | 1991-10-18 | 1997-04-01 | Lange, Iii; Louis G. | Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion |
CA2098167C (en) * | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
CA2128044C (en) * | 1993-08-05 | 2007-02-20 | Klaus-Dieter Bremer | Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor |
US5667775A (en) * | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5569452A (en) * | 1993-08-31 | 1996-10-29 | Tsrl, Inc. | Pharmaceutical formulation having enhanced bile acid binding affinity |
TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
US5545414A (en) * | 1995-03-22 | 1996-08-13 | Abbott Laboratories | Cholesterol lowering food product |
JP3832871B2 (ja) * | 1995-04-03 | 2006-10-11 | 日本製粉株式会社 | リパーゼ阻害剤 |
DE69633502T2 (de) | 1995-12-26 | 2006-02-23 | Suntory Ltd. | Procyanidin als den aktiven bestandteil enthaltende mittel gegen fettleibigkeit |
US5612026A (en) * | 1996-01-25 | 1997-03-18 | The Procter & Gamble Company | Cholesterol lowering drink mix compositons |
US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
JP3807464B2 (ja) | 1997-11-17 | 2006-08-09 | 康二 嘉島 | 肥満防止剤 |
GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
RU2222335C2 (ru) | 1998-01-09 | 2004-01-27 | Джензайм Корпорейшн | Жиросвязывающие полимеры |
FI113356B (fi) | 1998-05-20 | 2004-04-15 | Upm Kymmene Corp | Pakkauksenmuodostuslaite |
TR200100472T2 (tr) * | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler |
ES2242413T3 (es) * | 1998-08-14 | 2005-11-01 | F. Hoffmann-La Roche Ag | Composiciones farmaceuticas que contienen inhibidores de lipasa. |
NZ510311A (en) | 1998-09-08 | 2003-08-29 | Smithkline Beecham Corp | Lipstatin derivative - soluble fiber tablets |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
ATE271392T1 (de) | 1999-01-22 | 2004-08-15 | Hunza Di Pistolesi Elvira & C | Lipoproteinkomplexe und zusammensetzungen, die diese enthalten |
AR025587A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
AR025609A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
WO2002009815A2 (en) * | 2000-07-28 | 2002-02-07 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
-
2001
- 2001-07-19 WO PCT/EP2001/008363 patent/WO2002009815A2/en active IP Right Grant
- 2001-07-19 JP JP2002515366A patent/JP4265911B2/ja not_active Expired - Lifetime
- 2001-07-19 CZ CZ20030582A patent/CZ302087B6/cs not_active IP Right Cessation
- 2001-07-19 KR KR1020037001277A patent/KR100572785B1/ko active IP Right Grant
- 2001-07-19 ME MEP-905/08A patent/MEP90508A/hr unknown
- 2001-07-19 AT AT01969439T patent/ATE279961T1/de active
- 2001-07-19 PT PT01969439T patent/PT1307264E/pt unknown
- 2001-07-19 AU AU8969901A patent/AU8969901A/xx active Pending
- 2001-07-19 SI SI200130249T patent/SI1307264T1/xx unknown
- 2001-07-19 CA CA002416901A patent/CA2416901C/en not_active Expired - Lifetime
- 2001-07-19 RU RU2003104801/15A patent/RU2241462C2/ru active
- 2001-07-19 CN CNB018135196A patent/CN100423715C/zh not_active Expired - Lifetime
- 2001-07-19 MX MXPA03000771A patent/MXPA03000771A/es active IP Right Grant
- 2001-07-19 DE DE60106623T patent/DE60106623T2/de not_active Expired - Lifetime
- 2001-07-19 PL PL366105A patent/PL204443B1/pl unknown
- 2001-07-19 ES ES01969439T patent/ES2230362T3/es not_active Expired - Lifetime
- 2001-07-19 AU AU2001289699A patent/AU2001289699B2/en not_active Expired
- 2001-07-19 BR BRPI0112799A patent/BR0112799B1/pt not_active IP Right Cessation
- 2001-07-19 HU HU0301281A patent/HU229292B1/hu unknown
- 2001-07-19 IL IL15400801A patent/IL154008A0/xx unknown
- 2001-07-19 RS YUP-50/03A patent/RS50397B/sr unknown
- 2001-07-19 EP EP01969439A patent/EP1307264B1/en not_active Expired - Lifetime
- 2001-07-19 NZ NZ523684A patent/NZ523684A/en not_active IP Right Cessation
- 2001-07-24 JO JO2001125A patent/JO2320B1/en active
- 2001-07-24 PE PE2001000743A patent/PE20020336A1/es active IP Right Grant
- 2001-07-25 US US09/912,957 patent/US6756364B2/en not_active Expired - Lifetime
- 2001-07-26 PA PA20018523201A patent/PA8523201A1/es unknown
- 2001-07-26 MY MYPI20013543 patent/MY127247A/en unknown
- 2001-07-26 AR ARP010103574A patent/AR033548A1/es not_active Application Discontinuation
- 2001-07-27 UY UY26860A patent/UY26860A1/es not_active Application Discontinuation
- 2001-07-27 GT GT200100152A patent/GT200100152A/es unknown
- 2001-07-28 EG EG20010821A patent/EG24357A/xx active
- 2001-09-04 TW TWNEWPHARMA patent/TWI275395B/zh not_active IP Right Cessation
-
2003
- 2003-01-16 ZA ZA200300456A patent/ZA200300456B/en unknown
- 2003-01-16 IL IL154008A patent/IL154008A/en active IP Right Grant
- 2003-01-17 HR HR20030029A patent/HRP20030029B1/xx not_active IP Right Cessation
- 2003-01-24 EC EC2003004450A patent/ECSP034450A/es unknown
- 2003-01-27 NO NO20030418A patent/NO330546B1/no not_active IP Right Cessation
- 2003-01-27 MA MA27015A patent/MA26937A1/fr unknown
- 2003-11-20 US US10/718,049 patent/US20040105838A1/en not_active Abandoned
-
2004
- 2004-02-27 HK HK04101443A patent/HK1058636A1/xx not_active IP Right Cessation
-
2005
- 2005-02-18 US US11/062,086 patent/US20050136030A1/en not_active Abandoned
-
2006
- 2006-08-07 US US11/499,955 patent/US20060269510A1/en not_active Abandoned
-
2008
- 2008-09-09 JP JP2008230880A patent/JP2009073833A/ja active Pending
-
2010
- 2010-04-20 US US12/763,794 patent/US8071571B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP90508A (hr) | Nova farmaceutska smješa | |
BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
ATE294158T1 (de) | Ein monoether von probucol und methoden zur hemmung der vcam-1 expression | |
WO2001062280A3 (en) | Lipase-containing composition and methods of use thereof | |
ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
TR200000927T2 (tr) | Prostaglandin agonistleri ve kemik bozukluklarının tedavisi | |
ATE232873T1 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
HUP0103160A2 (hu) | Pulmonalis betegségek kezelésére alkalmas PDE4 inhibítort tartalmazó gyógyászati készítmények | |
ATE451369T1 (de) | Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes | |
NO20030845D0 (no) | Utvalgte fusjonerte pyrrolokarbazoler | |
ATE416761T1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
DE60013098D1 (de) | Zusammensetzung zur hautdesinfizierung | |
WO2003072593A3 (en) | Bone targeting peptides | |
DE60141636D1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
DE60327811D1 (de) | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen | |
AR039664A1 (es) | Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan | |
BR0210493A (pt) | Composição, e, método para remover cerume humano | |
BR0008382A (pt) | Formulação de liberação controlada para tratamento de copd | |
DE60329326D1 (de) | Tace inhibitoren | |
TR200200494T2 (tr) | Yağlı asit sintazı inhibitörleri. | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
ATE319689T1 (de) | Naphthamidin-urokinasinhibitoren | |
DK1144348T3 (da) | LTA4-hydrolaseinhibitorer | |
DE60111921D1 (de) | Dextrinhaltige zusammensetzungen zur vermeidung von adhäsionen |